A Study of Elenestinib in Healthy Adult Female Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.

Key facts

Study ID
NCT07388511
Run by
Blueprint Medicines Corporation
People needed
20
Starts
2026-02-05
Expected to finish
2026-04-02
Last updated by the study team
2026-04-20

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.